Drugs / Ethyl-EPA
Ethyl-EPA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00146211 | Sep 2005 → Aug 2007 | Huntington disease | Amarin Neuroscience Ltd | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ethyl-EPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00146211 ↗ |
| Known as | ethyl-eicosapentaenoic acid | “ethyl-eicosapentaenoic acid (ethyl-EPA), an omega-3 fatty acid” PMID 19064745 ↗ Dec 2008 |
| Known as | Miraxion | “Ethyl-EPA (Miraxion™)” NCT00146211 ↗ |
| Modality | Other / unclassified | “ethyl-eicosapentaenoic acid (ethyl-EPA), an omega-3 fatty acid” PMID 19064745 ↗ Dec 2008 |